Chronic beryllium disease: A model of interaction between environmental exposure and genetic predisposition. Pathogenesis and clinical features (Part 2);Bérylliose pulmonaire chronique (2e partie): Pathogénie, expression clinique, prévention et législation

Revue des Maladies Respiratoires

Volumn 22, Issue 2 C1, 2005, Pages 271-287

  Marchand Adam, S ^a,b   Guillon, F ^a   Brauner, M ^a   Valeyre, D ^a  

^a AVICENNE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Berylliosis; Beryllium; Fibrosis; Hypersensitivity; Sarcoidosis

Indexed keywords

BERYLLIUM; CD4 ANTIGEN; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; BERYLLIOSIS; CHRONIC DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; DUST EXPOSURE; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LYMPHOCYTE PROLIFERATION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL LUNG DISEASE; PATHOGENESIS; REVIEW; SARCOIDOSIS;

EID: 18744392562     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200539979     Document Type: Review

References (184)

1. Van Ordstrand H, Hugues R, DeNardi J, Carmody M: Beryllium poisoning. JAMA 1945; 129: 1084-90.
2. Hardy H, Tabershaw I: Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 1946; 28: 197-211.
3. Occupational Safety and Health Administration (OSHA): Toxic and hazardous substances 1989: Table Z-1. 29 CFR XVII; section 1910.1000.
4. Yoshida T, Shima S, Nagaoka K, Taniwaki H, Wada A, Kurita H, Morita K: A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Ind Health 1997; 35: 374-9.
5. Kelleher PC, Martyny JW, Mroz MM, Maier LA, Ruttenber AJ, Young DA, Newman LS: Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001; 43: 238-49.
6. e ed. Philadelphia: Lippincott Raven; 1998: 1017-31.
7. Sterner J, Eisenbud M: Epidemiology of beryllium intoxication. Arch Industr Hyg Occup Med 1951; 4: 123-31.
8. Curtis G: Cutaneous hypersensitivity due to beryllium. Archs Dermatol Syph 1951; 64: 470-82.
9. Votto JJ, Barton RW, Gionfriddo MA, Cole SR, McCormick JR, Thrall RS: A model of pulmonary granulomata induced by beryllium sulfate in the rat. Sarcoidosis 1987; 4: 71-6.
10. Goel KA, Agrawal VP, Garg V: Pulmonary toxicity of beryllium in albino rat. Bull Environ Contam Toxicol 1980; 24: 59-64.
11. Nikula KJ, Swafford DS, Hoover MD, Tohulka MD, Finch GL: Chronic granulomatous pneumonia and lymphocytic responses induced by inhaled beryllium metal in A/J and C3H/HeJ mice. Toxicol Pathol 1997; 25: 2-12.
12. Barna BP, Chiang T, Pillarisetti SG, Deodhar SD: Immunologic studies of experimental beryllium lung disease in the guinea pig. Clin Immunol Immunopathol 1981; 20: 402-11.
13. Haley PJ, Pavia KF, Swafford DS, Davila DR, Hoover MD, Finch GL: The comparative pulmonary toxicity of beryllium metal and beryllium oxide in cynomolgus monkeys. Immunopharmacol Immunotoxicol 1994; 16: 627-44.
14. Finch GL, Hoover MD, Hahn FF, Nikula KJ, Belinsky SA, Haley PJ, Griffith WC: Animal models of beryllium-induced lung disease. Environ Health Perspect 1996; 104: 973-9.
15. Haley PJ, Swafford DS, Finch GL, Hoover MD, Muggenburg BA, Johnson NF: Immunologic specificity of lymphocyte cell lines from dogs exposed to beryllium oxide. Immunopharmacol Immunotoxicol 1997; 19: 459-71.
16. Hanifin J, Epstein W, Cline M: in vitro studies of granulomatous hypersensibility to beryllium. J Invest Dermatol 1970; 55: 284-8.
17. Stuart B, Lioly, Phalen R: Particle size-selective sampling in establishing threshold limit values. Appl Ind Hyg 1986; 1: 138-44.
18. Sakaguchi T, Sakaguchi S, Nakamura I, Kagami M: Effects of beryllium chloride on cultured cells. Sangyo Igaku 1984; 26: 224-9.
19. Togna G, Togna AR, Russo P, Caprino L: Toxicological effects of beryllium on platelets and vascular endothelium. Toxicol Appl Pharmacol 1997; 144: 262-7.
20. Lavastre V, Roberge CJ, Pelletier M, Gauthier M, Girard D: Toxaphene, but not beryllium, induces human neutrophil chemotaxis and apoptosis via reactive oxygen species (ROS): involvement of caspases and ROS in the degradation of cytoskeletal proteins. Clin Immunol 2002; 104: 40-8.
21. Finch GL, Verburg RJ, Mewhinney JA, Eidson AF, Hoover MD: The effect of beryllium compound solubility on in vitro canine alveolar macrophage cytotoxicity. Toxicol Lett 1988; 41: 97-105.
22. Kang KY, Bice D, D'Amato R, Ziskind M, Salvaggio J: Effects of asbestos and beryllium on release of alveolar macrophage enzymes. Arch Environ Health 1979; 34: 133-40.
23. Eidson AF, Taya A, Finch GL, Hoover MD, Cook C: Dosimetry of beryllium in cultured canine pulmonary alveolar macrophages. J Toxicol Environ Health 1991; 34: 433-48.
24. Sawyer RT, Fadok VA, Kittle LA, Maier LA, Newman LS: Beryllium-stimulated apoptosis in macrophage cell lines. Toxicology 2000; 149: 129-42.
25. Kittle L, Sawyer R, Fadok V, Maier L, Newman L: Beryllium-induced apoptosis. Am J Respir Dis Crit Care Med 2000; 163: A731.
26. Kittle LA, Sawyer RT, Fadok VA, Maier LA, Newman LS: Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 101-13.
27. Hart BA, Pittman DG: The uptake of beryllium by the alveolar microphage. J Reticuloendothel Soc 1980; 27: 49-58.
28. Newman LS: To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science 1993; 262: 197-8.
29. Scott BL, Wang Z, Marrone BL, Sauer NN: Potential binding modes of beryllium with the class II major histocompatibility complex HLA-DP: a combined theoretical and structural database study. J Inorg Biochem 2003; 94: 5-13.
30. Lee JY, Atochina O, King B, Taylor L, Elloso M, Scott P, Rossman MD: Beryllium, an adjuvant that promotes gamma interferon production. Infect Immun 2000; 68: 4032-9.
31. Richeldi L, Sorrentino R, Saltini C: HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262: 242-4.
32. Carthy D, Mac Gregor A, Awomoi A, Rigby A, Thomson W, Donn R, Silman A, Ollier W: HLA DP 0201 is associated with particular clinical features of rheumatoid arthritis. Rev Rhum Engl Ed 1995; 62: 163.
33. Bugawanv T, Angelini G, Larrick J, Aurichio S, Ferrara G, Erlich H: A combinaison of a particular HLA DPB allele and an HLA DQ heterodimer confers susceptibility to coeliac disease. Nature 1989; 339: 470-3.
34. Rihs H, Conrad K, Mehlhorn J, May Taube K, Welticke B, Frank K, Baur X: Molecular analysis of HLA-DPB1 alleles in idiopathic systemic sclerosis patients and uranium miners with systemic sclerosis. Int Arch Allergy Immunol 1996; 109: 216-22.
35. Taylor G, Robinson D, Binchy A, Birch J, Stevens R, Jones P, Carr T, Dearden S, Gokhale A: Preliminary evidence of an association between and childhood common acute lymphoblastic leukaemia supports an infectious aetiology. Leukemia 1995; 9: 440.
36. Taylor G, Gokhale D, Crowther D, Woll P, Harris M, Ryder D, Ayres M, Radford J: Further investigation of the rôle of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. Br J Cancer 1999; 80: 1405-11.
37. Varney M, Lester S, McCluskey J, Gao X, Tait P: Matching for HLA DPA1 et DPB1 alleles unrelated bone marrow transplantation. Human Immunol 1999; 60: 532-8.
38. Potolicchio H, Mosconi G, Forni A, Nemery B, Seghizzi P, RS: Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA DPB chain. Eur J Immunol 1997; 27: 2741-3.
39. Potolicchio I, Festucci A, Hausler P, Sorrentino R: HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Eur J Immunol 1999; 29: 2140-7.
40. Amicosante M, Sanarico N, Berretta F, Arroyo J, Lombardi G, Lechler R, Colizzi V, Saltini C: Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol 2001; 62: 686-93.
41. Berretta F, Butler RH, Diaz G, Sanarico N, Arroyo J, Fraziano M, Aichinger G, Wucherpfennig KW, Colizzi V, Saltini C, Amicosante M: Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens 2003; 62: 459-71.
42. Arroyo J, Alvarez AM, Nombela C, Sanchez-Perez M: The role of HLA-DP beta residue 69 in the definition of antibody-binding epitopes. Hum Immunol 1995; 43: 219-26.
43. Diaz G, Catalfamo M, Coiras M, Alvarez A, Jaraquemada D, Nombela C, Sanchez Perez M, Arroyo J: HLA DPB residue 69 plays a crucial role in allorecognition. Tissue Antigens 1998; 52: 27-36.
44. Saltini C, Winestock K, Kitby M, Pinkston P, Crystal RG: Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989; 320: 1103-9.
45. Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL: Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110: 1473-82.
46. Saltini C, Amicosante M, Franchi A, Lombardi G, Richeldi L: Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998; 12: 1463-75.
47. Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL: Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000; 97: 12717-22.
48. Lombardi G, Germain C, Uren J, Fiorillo MT, du Bois RM, Jones-Williams W, Saltini C, Sorrentino R, Lechler R: HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001; 166: 3549-55.
49. Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL: Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110: 1473-82.
50. Comment C, Kotzin B, Schumacher B, Newman L: Preferential use of cell antigen receptors in beryllium disease. Am J Respir Crit Care Med 1994; 149: A264.
51. Fontenot AP, Kotzin BL, Comment CE, Newman LS: Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. Am J Respir Cell Mol Biol 1998; 18: 581-9.
52. Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M, Barker EA, Newman LS, Kotzin BL: Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol 2002; 168: 3627-34.
53. Fontenot AP, Gharavi L, Bennett SR, Canavera SJ, Newman LS, Kotzin BL: CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J Clin Invest 2003; 112: 776-84.
54. Tinkle SS, Kittle LA, Schumacher BA, Newman LS: Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997; 158: 518-26.
55. Maier LA, Sawyer RT, Tinkle SS, Kittle LA, Barker EA, Balkissoon R, Rose C, Newman LS: IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001; 17: 403-15.
56. Barna BP, Dweik RA, Farver CF, Culver D, Yen-Lieberman B, Thomassen MJ: Nitric oxide attenuates beryllium-induced IFN gamma responses in chronic beryllium disease: evidence for mechanisms independent of IL-18. Clin Immunol 2002; 103: 169-75.
57. Tinkle SS, Newman LS: Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 1997; 156: 1884-91.
58. Sawyer RT, Kittle LA, Hamada H, Newman LS, Campbell PA: Beryllium-stimulated production of tumor necrosis factor-alpha by a mouse hybrid macrophage cell line. Toxicology 2000; 143 : 235-47.
59. Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, Dweik R, Saltini C: HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J 2002; 20: 1174-8.
60. Tinkle SS, Kittle LA, Newman LS: Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. J Immunol 1999; 163: 2747-53.
61. Deodhar SD, Barna B, Van Ordstrand HS: A study of the immunologic aspects of chronic berylliosis. Chest 1973; 63: 309-13.
62. Vasilyeva EV, Nikitina LS, Orlova AA: Concentration of immunoglobulins in berylliosis. J Hyg Epidemiol Microbiol Immunol 1977; 21: 254-60.
63. Resnick H, Roche M, Morgan WK: Immunoglobulin concentrations in berylliosis. Am Rev Respir Dis 1970; 101: 504-10.
64. Resnick H, Morgan WK: Immunoglobulin levels in berylliosis. Inhaled Part 1970; 2: 589-97.
65. Chesnokov VA, Belova AA: Chronic exposure to low concentrations of beryllium on the level of human serum immunoglobulins. Gig Tr Prof Zabol 1979: 38-40.
66. Izumi T, Kobara Y, Inui S, Tokunaga R, Orita Y, Kitano M, Williams WJ: The first seven cases of chronic beryllium disease in ceramic factory workers in Japan. Ann N Y Acad Sci 1976; 278: 636-53.
67. Newman LS, Campbell PA: Mitogenic effect of beryllium sulfate on mouse B lymphocytes but not T lymphocytes in vitro. Int Arch Allergy Appl Immunol 1987; 84: 223-7.
68. Clarke SM: A novel enzyme-linked immunosorbent assay (ELISA) for the detection of beryllium antibodies. J Immunol Methods 1991; 137: 65-72.
69. Inoue Y, King TE, Jr., Tinkle SS, Dockstader K, Newman LS: Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996; 149: 2037-54.
70. Inoue Y, Cornebise M, Daniloff E, Lloyd J, Tinkle S, King TE, Jr., Newman LS: Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. Chest 1996; 109: 43S-44S.
71. Mornex JF, Leroux C, Greenland T, Ecochard D: From granuloma to fibrosis in interstitial lung diseases: molecular and cellular interactions. Eur Respir J 1994; 7: 779-85.
72. Lehnert NM, Gary RK, Marrone BL, Lehnert BE: Inhibition of normal human lung fibroblast growth by beryllium. Toxicology 2001; 160: 119-27.
73. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R: Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001; 43: 231-7.
74. Maier LA: Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 2001; 16: 514-20.
75. Solvignon L: La bérylliose: maladie méconnue? Bilan épidémiologique actuel en France et dans le monde, thèse de médecine. Université Claude Bernard, Lyon I; 1995: p. 98.
76. Hasan FM, Kazemi H: Chronic beryllium disease: a continuing epidemiologic hazard. Chest 1974; 65: 289-93.
77. Newman LS: Beryllium disease and sarcoidosis: clinical and laboratory links. Sarcoidosis 1995; 12: 7-19.
78. Hardy HL: Beryllium poisoning-lessons in control of man-made disease. N Engl J Med 1965; 273: 1188-99.
79. Hasejima N, Kobayashi H, Takezawa S, Yamato K, Kadoyama C, Kawano Y: Chronic Beryllium disease after exposure to low-beryllium-content copper. Nihon Kyobu Shikkan Cakkai Zasshi 1995; 33: 1105-10.
80. Hasan FM, Kazemi H: Progress report. U.S. Beryllium Case Registry, 1972. Am Rev Respir Dis 1973; 108: 1252-3.
81. Andrews JL, Kazemi H, Hardy HL: Patterns of lung dysfunction in chronic beryllium disease. Am Rev Respir Dis 1969; 100: 791-800.
82. Iles PB: Multiple bronchial stenoses: treatment by mechanical dilatation. Thorax 1981; 36: 784-6.
83. Freiman DG, Hardy HL: Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. beryllium case registry. Hum Pathol 1970; 1: 25-44.
84. Williams WJ: United Kingdom Beryllium Registry: mortality and autopsy study. Environ Health Perspect 1996; 104: 949-51.
85. Vervloet A: La bérylliose professionnelle: a propos de six cas et étude bibliographique. Thèse de médecine. Faculté de médecine de Grenoble; 2001: p 130.
86. Busuttil A: Granulomas in nasal polyps. J Laryngol Otol 1975; 89: 1087-94.
87. Berlinger NT: Inhalant granulomas: silicosis, asbestosis, berylliosis. Otolaryngol Clin North Am 1982; 15: 561-6.
88. Stoeckle J, Hardy H, Weber A: chronic beryllium disease. Long-Term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46: 545-61.
89. Yao JJ, Hu SY: A study of immunological indices for diagnosis of chronic berylliosis. Biomed Environ Sci 1989; 2: 318-24.
90. Sprince NL, Kazemi H, Hardy HL: Current (1975) problem of differentiating between beryllium disease and sarcoidosis. Ann N Y Acad Sci 1976; 278: 654-64.
91. Vasil'eva EV, Kharlamova SF: Antinuclear and antimitochondrial antibodies in persons exposed to beryllium. Gig Tr Prof Zabol 1976: 20-3.
92. Kelley WN, Goldfinger SE, Hardy HL: Hyperuricemia in chronic beryllium disease. Ann Intern Med 1969; 70: 977-83.
93. Sharma OP: Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000; 6: 442-7.
94. Kriebel D, Brain JD, Sprince NL, Kazemi H: The pulmonary toxicity of beryllium. Am Rev Respir Dis 1988; 137: 464-73.
95. Harris J, Bartelson BB, Barker E, Balkissoon R, Kreiss K, Newman LS: Serum neopterin in chronic beryllium disease. Am J Ind Med 1997; 32: 21-6.
96. Maier LA, Kittle LA, Mroz MM, Newman LS: Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med 2003; 43: 592-601.
97. Newman LS, Orton R, Kreiss K: Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992; 146: 39-42.
98. Epstein PE, Dauber JH, Rossman MD, Daniele RP: Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonias. Ann Intern Med 1982; 97: 213-6.
99. Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B, Mroz MM, King TE, Jr: Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med 1994; 150: 135-42.
100. Schepers G: The mineral content of lung in chronic berylliosis. J Dis Chest 1962; 42: 600-7.
101. Williams WJ, Kelland D: New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA). J Clin Pathol 1986; 39: 900-1.
102. Williams WJ, Wallach ER: Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis and other granulomatous diseases. Sarcoidosis 1989; 6: 111-7.
103. Williams WJ: Diagnostic criteria for chronic beryllium disease (CBD) based on the UK registry 1945-1991. Sarcoidosis 1993; 10: 41-3.
104. Apostoli P, Schaller K: Urinary beryllium - a suitable tool for assessing occupational and environmental beryllium exposure? Int Arch Occup Environ Health 2001; 74: 162-6.
105. Wegner R, Heinrich-Ramm R, Nowak D, Olma K, Poschadel B, Szadkowski D: Lung function, biological monitoring, and biological effect monitoring of gemstone cutters exposed to beryls. Occup Environ Med 2000; 57: 133-9.
106. nd ed; Butterworths, London: 1984. 333p.
107. Stoeckle JD, Hardy HL, Weber AL: Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46: 545-61.
108. Sawyer RT, Maier LA, Kittle LA, Newman LS: Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol 2002; 2: 249-61.
109. Klein JT, Horn TD, Forman JD, Silver RF, Teirstein AS, Moller DR: Selection of oligoclonal V beta-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol 1995; 154: 1450-60.
110. Nishimura M: Clinical and experimental studies on acute beryllium disease. Nagoya J Med Sci 1966; 29: 17-44.
111. Waksman BH: the diagnosis of beryllium disease, with special reference to patch test. AMA Arch Ind Health 1959; 19: 154.
112. Bobka CA, Stewart LA, Engelken GJ, Golitz LE, Newman LS: Comparison of in vivo and in vitro measures of beryllium sensitization. J Occup Environ Med 1997; 39: 540-7.
113. Fields S: Toxic beryllium: new solutions for a chronic problem. Environ Health Perspect 2001; 109: A74-9.
114. Kreiss K, Newman LS, Mroz MM, Campbell PA: Screening blood test identifies subclinical beryllium disease. J Occup Med 1989; 31: 603-8.
115. Newman LS: Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996; 104: 953-6.
116. Van Ganse WF, Oleffe J, Van Hove W, Groetenbriel C: Lymphocyte transformation in chronic pulmonary berylliosis. Lancet 1972; 1: 1023.
117. Rossman MD, Kern JA, Elias JA, Cullen MR, Epstein PE, Preuss OP, Markham TN, Daniele RP: Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med 1988; 108: 687-93.
118. Stokes RF, Rossman MD: Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med 1991; 33: 23-8.
119. Deubner DC, Goodman M, Iannuzzi J: Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hyg 2001; 16: 521-6.
120. Markham TN: Screening for chronic beryllium disease using beryllium specific lymphocyte proliferation testing. Int Arch Occup Environ Health 1996; 68: 405-7.
121. Rom WN, Lockey JE, Bang KM, Dewitt C, Johns RE, Jr: Reversible beryllium sensitization in a prospective study of beryllium workers. Arch Environ Health 1983; 38: 302-7.
122. Farris GM, Newman LS, Frome EL, Shou Y, Barker E, Habbersett RC, Maier L, Smith HN, Marrone BL: Detection of beryllium sensitivity using a flow cytometric lymphocyte proliferation test: the Immuno-Be-LPT. Toxicology 2000; 143: 125-40.
123. Price CD, Pugh A, Pioli EM, Williams WJ: Beryllium macrophage migration inhibition test. Ann N Y Acad Sci 1976; 278: 204-11.
124. Williams WR, Williams WJ: Comparison of lymphocyte transformation and macrophage migration inhibition tests in the detection of beryllium hypersensitivity. J Clin Pathol 1982; 35: 684-7.
125. Tepper LB, Hardy H, Chamberlin R: Toxicity of Beryllium Compounds. Amsterdam: Elsevier publishing compagny; 1961: pp 146-168.
126. Pappas GP, Newman LS: Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993; 148: 661-6.
127. Risk C, Epler GR, Gaensler EA: Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984; 85: 69-74.
128. Kriebel D, Sprince NL, Eisen EA, Greaves IA: Pulmonary function in beryllium workers: assessment of exposure. Br J Ind Med 1988; 45 : 83-92.
129. Newman LS, Buschman DL, Newell JD, Jr., Lynch DA: Beryllium disease: assessment with CT. Radiology 1994; 190: 835-40.
130. Aronchick JM, Rossman MD, Miller WT: Chronic beryllium disease: diagnosis, radiographic findings, and correlation with pulmonary function tests. Radiology 1987; 163: 677-82.
131. Newman LS, Kreiss K, King TE, Jr., Seay S, Campbell PA: Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989; 139: 1479-86.
132. Harris KM, McConnochie K, Adams H: The computed tomographic appearances in chronic berylliosis. Clin Radiol 1993; 47: 26-31.
133. Fabroni M: Patologia polmonare da poiveri di berillio. Med Lav 1935; 26: 297-303.
134. Naccache JM, Marchand-Adam S, Kambouchner M, Guillon F, Monnet I, Girard F, Brauner M, Valeyre D: Ground-glass computed tomography pattern in chronic beryllium disease: pathologic substratum and evolution. J Comput Assist Tomogr 2003; 27: 496-500.
135. Daniloff EM, Lynch DA, Bartelson BB, Newell JD, Jr., Bernstein SM, Newman LS: Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med 1997; 155: 2047-56.
136. Morrone N, Campos Neto J, Shibaca NP, Pratscher P, de Lima Filho MT: Importance of scintigraphy with gallium (67 Ga) in pneumology. Rev Paul Med 1982; 100: 30-3.
137. Deseran MW, Colletti PM, Ratto D, Ansari AN, Siegel ME: Chronic berylliosis. Demonstration by gallium-67 imaging and magnetic resonance imaging. Clin Nucl Med 1988; 13: 509-11.
138. Palmer PE, Stadalnik RC, Khalkhali I: Non-bony uptake of technetium-99m MDP in berylliosis. Br J Radiol 1980; 53: 1195-7.
139. Diot P, Le Pape A, Nolibe D, Normier G, Binz H, Revillard JP, Lasfargues G, Lavandier M, Lemarie E: Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berylliosis: results from an experimental model. Br J Ind Med 1992; 49: 359-64.
140. Williams WJ: The beryllium granuloma. Proc R Soc Med 1971; 64: 946-8.
141. Williams WJ, Fry E, James EM: The fine structure of beryllium granulomas. Acta Pathol Microbiol Scand 1972; 233: 195-202.
142. Williams WJ: Granulomas in sarcoidosis and chronic beryllium disease. Verb Dtsch Ges Pathol 1980; 64: 177-80.
143. Rossman MD: Chronic Beryllium Disease: Diagnosis and Management. Environ Health Perspect 1996; 104S: 945-7.
144. st ed. Boston: Little, Brown; 1983: pp. 481-490.
145. Rossman MD, Kreider ME: Is chronic beryllium disease sarcoidosis of known etiology? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 104-9.
146. Muller-Quernheim J, Zissel G, Schopf R, Vollmer E, Schlaak M: Differential diagnosis of berylliosis/sarcoidosis in a dental technician. Dtsch Med Wochenschr 1996; 121: 1462-6.
147. Fireman E, Haimsky E, Noiderfer M, Priel I, Lerman Y: Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidasis Vasc Diffuse Lung Dis 2003; 20: 144-8.
148. De Vuyst P, Dumortier P, Schandene L, Estenne M, Verhest A, Yernault JC: Sarcoidlike lung granulomatosis induced by aluminum dusts. Am Rev Respir Dis 1987; 135: 493-7.
149. Redline S, Barna BP, Tomashefski JF, Jr., Abraham JL: Granulomatous disease associated with pulmonary deposition of titanium. Br J Ind Med 1986; 43: 652-6.
150. Werfel U, Schneider J, Rodelsperger K, Kotter J, Popp W, Woitowitz HJ, Zieger G: Sarcoid granulomatosis after zirconium exposure with multiple organ involvement. Eur Respir J 1998; 12: 750.
151. Mital OP, Narang RK, Misra US, Sachan AS, Saxena H: Barium granuloma following bronchography: a case report. Indian J Chest Dis 1975; 17: 55-7.
152. Cortez P, Marques F: Vineyrard sprayer's lung: A new occupational disease. Thorax 1969; 24: 678-88.
153. Cugell D: the hard metal diseases. Clin Chest Med 1992; 13: 269-79.
154. Drent M, Bomans PH, Van Suylen RJ, Lamers RJ, Bast A, Wouters EF: Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med 2000; 94: 815-20.
155. Newman L, Mroz M, Schumacher B, Daniloff TE, Kreiss K: Beryllium sensitization precedes chronic beryllium disease. Am Rev Respir Dis (suppl) 1992; 145: A324.
156. 3. Am J Ind Med 1996; 30: 16-25.
157. Eisenbud M, Lisson J: Epidemiological aspects of beryllium-induced nonmalignant lung disease: a 30-year update. J Occup Med 1983; 25: 196-202.
158. Kreiss K, Mroz MM, Zhen B, Wiedemann H, Barna B: Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997; 54: 605-12.
159. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, Dweik RA, Wiedemann HP, Deubner DC, Tinelli C: Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001; 18: 677-84.
160. Newman L, Balkissoon R, Daniloff E, Solida M, Mroz M: Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year. Am J Respir Crit Care 1998; 157: A145.
161. Williams WJ: On the differential diagnosis of chronic beryllium disease and sarcoidosis. Am Rev Respir Dis 1990; 142: 739-40.
162. Hardy H: Differential diagnosis between beryllium poisoning and sarcoidosis. Am Rev Tuberc 1956; 74: 885-95.
163. Sprince NL, Kanarek DJ, Weber AL, Chamberlin RJ, Kazemi H: Reversible respiratory disease in beryllium workers. Am Rev Respir Dis 1978; 117: 1011-7.
164. O'Brien AA, Moore DP, Keogh JA: Pulmonary berylliosis on corticosteroid therapy, with cavitating lung lesions and aspergillomata-report on a fatal case. Postgrad Med J 1987; 63: 797-9.
165. Infante PF, Wagoner JK, Sprince NL: Mortality patterns from lung cancer and nonneoplastic respiratory disease among white males in the beryllium case registry. Environ Res 1980; 21: 35-43.
166. Peyton M, Worcester J: exposure data and epidemiology of beryllium casse registry-1958. Arch Indust Health 1959; 19: 94-9.
167. Steenland K, Ward E: Lung cancer incidence among patients with beryllium disease: a cohort mortality study. J Natl Cancer Inst 1991; 83: 1380-5.
168. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, Newman LS: Influence of MHC CLASS II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003; 171: 6910-8.
169. Redding RA, Hardy HL, Gaensler EA: Beryllium disease: a 16-year follow-up case study. Respiration 1968; 25: 263-78.
170. Gaensler EA, Verstraeten JM, Weil WB, Cugell DW, Marks A, Cadigan JB, Jr., Jones RH, Ellicott MF: Respiratory pathophysiology in chronic beryllium disease; review of thirty cases with some observations after long-term steroid therapy. AMA Arch Ind Health 1959; 19: 132-45.
171. Sendelbach LE, Lindenschmidt RC, Witschi HP: The effect of cyclosporin A on pulmonary fibrosis induced by butylated hydroxytoluene, bleomycin and beryllium sulfate. Toxicol Lett 1985 ; 26 : 169-73.
172. Brichon PY, Blin D, Noirclerc M, Magne JL, Blanc Jouvan F, Pison C, Romand P, Brambilla E, Barnoud D, Farah I: Diffuse bronchomalacia after double lung transplantation. Thoughts apropos of a case. Ann Chir 1992; 46: 105-9.
173. Shukla S, Sharma P, Johri S, Mathur R: Influence of chelating agents on the toxicity and distribution of beryllium in rats. J Appl Toxicol 1998; 18: 331-5.
174. Sharma P, Johri S, Shukla S: Beryllium-induced toxicity and its prevention by treatment with chelating agents. J Appl Toxicol 2000; 20: 313-8.
175. Sharma P, Shah A, Shukla S: Protective effect of Tiron (4,5-dihydroxybenzene-1,3-disulfonic acid disodium salt) against beryllium-induced maternal and fetal toxicity in rats. Arch Toxicol 2002; 76: 442-8.
176. Stange AW, Hilmas DE, Furman FJ: Possible health risks from low level exposure to beryllium. Toxicology 1996; 111: 213-24.
177. Holtzman NA: Medical and Ethical Issues in Genetic Screening-An Academic View. Environ Health Perspect 1996; 104S: 987-90.
178. Marshall E: Beryllium screening raises ethical issues. Science 1999; 285: 178-9.
179. McCunney RJ: Genetic testing: ethical implications in the workplace. Occup Med 2002; 17: 665-72.
180. Nicas M, Lomax GP: A cost-benefit analysis of genetic screening for susceptibility to occupational toxicants. J Occup Environ Med 1999; 41: 535-44.
181. Bartell SM, Ponce RA, Takaro TK, Zerbe RO, Omenn GS, Faustman EM: Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Anal 2000; 20: 87-99.
182. Weston A, Ensey J, Kreiss K, Keshava C, McCanlies E: Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med 2002; 41: 457-65.
183. Newman LS, Kreiss K: Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145: 1212-4.
184. Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, Monos D: HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73: 720-35.